Glucagon-like peptide 2 medications
Pro Research Analysisby 
Searched over 200M research papers
Glucagon-Like Peptide 2 Medications: Mechanisms and Therapeutic Potential
Glucagon-like peptide 2 (GLP-2) is a hormone released by intestinal endocrine cells, playing a key role in gut health. However, its use as a medication is limited by rapid breakdown in the body. To overcome this, researchers have developed GLP-2 analogs with structural modifications—such as amino acid substitution, lipidation, and protein fusion—to extend their half-life and enhance their biological effects. These advances have been made possible by a better understanding of the GLP-2 receptor’s structure, leading to more effective and longer-lasting GLP-2 medications. There is also growing interest in creating multifunctional molecules that target multiple pathways to further improve therapeutic outcomes for patients with gastrointestinal diseases and other conditions where GLP-2 may be beneficial Gong2025Suzuki2020.
GLP-1 and GLP-2: Differences and Overlapping Therapeutic Strategies
While GLP-2 medications are primarily focused on gut health, glucagon-like peptide 1 (GLP-1) analogs are widely used in the treatment of type 2 diabetes. Both GLP-1 and GLP-2 are derived from the same precursor molecule and are rapidly inactivated by the enzyme dipeptidyl peptidase IV, which has driven the development of modified peptide drugs for both targets. Innovations in drug design, such as multifunctional peptides and alternative delivery methods, are being explored for both GLP-1 and GLP-2 therapies, highlighting the broad potential of peptide-based medications in treating a range of diseases Gong2025Suzuki2020.
Clinical Benefits and Safety of GLP-1 Receptor Agonists
GLP-1 receptor agonists (GLP-1RAs) are a well-established class of medications for type 2 diabetes. They lower blood sugar by stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. Clinical trials show that GLP-1RAs reduce HbA1c by about 1% compared to placebo, and some agents (like liraglutide and exenatide) are more effective than insulin glargine or other oral diabetes drugs. These medications also promote weight loss and improve beta-cell function, though the latter effect does not persist after stopping treatment. The most common side effects are gastrointestinal, such as nausea, which usually decrease over time. Hypoglycemia risk is low unless combined with sulfonylureas or insulin .
Cardiovascular and Renal Protection with GLP-1RAs
Beyond glucose control, GLP-1RAs have been shown to reduce cardiovascular events in people with type 2 diabetes and high cardiovascular risk. They are now recommended by professional guidelines for patients with established atherosclerotic cardiovascular disease or multiple risk factors, regardless of baseline glucose control. GLP-1RAs are also beneficial for patients with obesity and advanced chronic kidney disease, offering additional options for those with limited cardiovascular risk-reducing therapies. These benefits are largely independent of their blood sugar-lowering effects Shepard2021Honigberg2020.
Access and Use of GLP-1 and GLP-2 Medications
Recent changes in clinical guidelines have led to fewer restrictions on GLP-1RAs in Medicare formularies, making these medications more accessible as first-line options for patients with diabetes and cardiorenal conditions. However, despite their proven benefits, GLP-1RAs remain underused, especially by cardiologists, and cost considerations may still limit access for some patients Wisniewski2024Honigberg2020.
Perioperative and Whole-Body Considerations
GLP-1RAs are considered safe to continue during the perioperative period for patients with diabetes, helping to maintain stable blood sugar and avoid complications associated with insulin infusions. Additionally, both GLP-1RAs and SGLT2 inhibitors offer whole-body protection, improving cardiovascular and renal outcomes in both diabetic and non-diabetic populations Dhatariya2024Shepard2021.
Conclusion
GLP-2 medications are advancing through innovative drug design to overcome rapid inactivation and improve gut health, while GLP-1 receptor agonists are well-established for diabetes management, with added benefits for cardiovascular and renal protection. Both classes of drugs are becoming more accessible and are being integrated into broader therapeutic strategies, offering significant benefits for patients with diabetes, cardiovascular disease, and other related conditions Gong2025Shyangdan2011Dhatariya2024+4 MORE.
Sources and full results
Most relevant research papers on this topic